Scholarlink

Introduction <p>To report 1.5-year real-world outcomes on the incidence of sterile intraocular inflammation (IOI) following intravitreal aflibercept 8&#xa0;mg injections, with emphasis on differences between vial and pre-filled syringe (PFS) use.</p> Methods <p>This retrospective multicenter study reviewed the electronic medical records of all patients who received aflibercept 8&#xa0;mg injections at Vista Augenklinik sites between March 1, 2024, and November 30, 2025. The primary outcome was the incidence of IOI per injection. Secondary analyses included stratification by treatment indication and by vial versus PFS administration.</p> Results <p>A total of 2631 injections were administered to 453 eyes of 398 patients. IOI was documented in 41 eyes (37 patients), corresponding to an incidence of 1.56% per injection (95% confidence interval [CI], 1.21–2.41), 9.05% per eye (95% CI, 7.13–13.0), and 9.30% per patient (95% CI, 7.0–13.32). Mean time to presentation was 7.3&#xa0;days (range 2–31) after a mean of 4.7 injections. All cases presented with anterior chamber and/or vitreous inflammation without posterior involvement. No retinal vasculitis or infiltrates were observed. Inflammation resolved with topical corticosteroids and/or nonsteroidal anti-inflammatory drugs (NSAIDs), with no significant change in best-corrected visual acuity (VA) compared to pre-event VA (20/32 versus 20/35 Snellen equivalent, <i>p</i> = 0.62). The incidence differed significantly between formulations: 2.26% per injection with the vial versus 0.21% per injection with the PFS (<i>p</i> = 0.010).</p> Conclusion <p>In a real-world setting, aflibercept 8&#xa0;mg was associated with a higher incidence of IOI than reported in pivotal trials, particularly when administered from vials. Conversion to the PFS markedly reduced the incidence, suggesting a formulation- or preparation-related effect. All cases were mild, anterior, and reversible under topical therapy without long-term visual impact.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lower Rates of Intraocular Inflammation with Aflibercept 8 mg Delivered via Pre-Filled Syringe Versus Vial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月14日

查看全文
  • Laura Hoffmann,
  • Katja Hatz

摘要

Introduction

To report 1.5-year real-world outcomes on the incidence of sterile intraocular inflammation (IOI) following intravitreal aflibercept 8 mg injections, with emphasis on differences between vial and pre-filled syringe (PFS) use.

Methods

This retrospective multicenter study reviewed the electronic medical records of all patients who received aflibercept 8 mg injections at Vista Augenklinik sites between March 1, 2024, and November 30, 2025. The primary outcome was the incidence of IOI per injection. Secondary analyses included stratification by treatment indication and by vial versus PFS administration.

Results

A total of 2631 injections were administered to 453 eyes of 398 patients. IOI was documented in 41 eyes (37 patients), corresponding to an incidence of 1.56% per injection (95% confidence interval [CI], 1.21–2.41), 9.05% per eye (95% CI, 7.13–13.0), and 9.30% per patient (95% CI, 7.0–13.32). Mean time to presentation was 7.3 days (range 2–31) after a mean of 4.7 injections. All cases presented with anterior chamber and/or vitreous inflammation without posterior involvement. No retinal vasculitis or infiltrates were observed. Inflammation resolved with topical corticosteroids and/or nonsteroidal anti-inflammatory drugs (NSAIDs), with no significant change in best-corrected visual acuity (VA) compared to pre-event VA (20/32 versus 20/35 Snellen equivalent, p = 0.62). The incidence differed significantly between formulations: 2.26% per injection with the vial versus 0.21% per injection with the PFS (p = 0.010).

Conclusion

In a real-world setting, aflibercept 8 mg was associated with a higher incidence of IOI than reported in pivotal trials, particularly when administered from vials. Conversion to the PFS markedly reduced the incidence, suggesting a formulation- or preparation-related effect. All cases were mild, anterior, and reversible under topical therapy without long-term visual impact.